Sarepta Therapeutics released three‑year follow-up data from its pivotal DMD trial showing durable motor-function benefit for Elevidys (delandistrogene moxeparvovec) versus historical controls, with the gap widening between years two and three. The company framed the results as a shift to an efficacy narrative after a year of safety scrutiny and slowing sales. Analysts noted the data may influence physician uptake and payer discussions as Sarepta seeks to restore commercial momentum.